

# Contents

<b>Foreword</b>	<b>xix</b>
<b>Preface</b>	<b>xxi</b>
<b>CHAPTER 1</b>	
<b>Statutory and Regulatory Scheme</b>	<b>1</b>
<hr/>	
I. The Drug Price Competition and Patent Term Restoration Act of 1984 (aka The Hatch-Waxman Act)	1
A. Impetus for Reform	1
II. Statutory Overview and Specific Amendments	3
A. General Compromise	3
B. Subsequent Amendments	4
III. Statutory Balancing: Incentives to Patentees and Generics	5
A. New Drug Application Filers	5
B. ANDA Filers	17
<b>CHAPTER 2</b>	
<b>Drug Approval Process—An Overview</b>	<b>25</b>
<hr/>	
I. Pre-NDA Filing	26
II. NDA Filing and Post-NDA Filing	27
III. The FDA Process for Securing Drug Approval for a Drug Under the ANDA Process	29
<b>CHAPTER 3</b>	
<b>Notice and Pre-Filing Considerations</b>	<b>33</b>
<hr/>	
I. The NDA Owner’s Pre-Notice Letter Investigation	33
A. Timeline for Receiving the Notice Letter	33
B. Pre-Suit Due Diligence and Review of Orange Book Listings	35

II.	Paragraph IV Notice Letters	42
	A. Requirements	42
	B. Estoppel and Reservation of Rights	43
	C. Confidentiality	44
	D. Considerations for the Notice Letter Recipient	45
III.	Considerations During the 45-Day Window	46
	A. Pre-Filing Investigation for NDA Holders	46
	B. The Thirty-Month Stay	47
	C. Protective Suits	48
	D. Joint Exclusivity	49
IV.	Declaratory Judgment Actions	50
	A. Requirements of the Declaratory Judgment Act	51
	B. The MMA's Three Additional Requirements	57
V.	Confidential Access	59
	A. Contents of Offer	59
	B. Jurisdictional Prerequisite	60
	C. Obligations to Negotiate or Review ANDA	61
VI.	NDA Owner and Generic Tension Regarding the Thirty-Month Stay	62
	A. The Thirty-Month Stay	62
	B. Modifying the Thirty-Month Stay	63
	C. Pediatric Exclusivity	65
	D. Considerations When Launching at Risk	66
VII.	The 180-Day Exclusivity Period	68
	A. Triggering Exclusivity Under the Pre-MMA Framework	69
	B. Triggering Exclusivity Under the Post-MMA Framework	70
	C. Obtaining Subject-Matter Jurisdiction	72
VIII.	Non-Paragraph IV ANDA Litigation	72

## CHAPTER 4

### Litigation Timeline

75

I.	Introduction	75
II.	Logistics Following Receipt of the Notice Letter	75
	A. Selecting Counsel	75
	B. Choosing a Forum	76
III.	Scheduling the Case	79
	A. Impact of FDA Review	79
	B. ANDA-Specific Local Rules	80
	C. Bifurcation	83
	D. Contention Discovery	83
	E. Discovery	84
	F. Claim Construction	85

---

G. Summary Judgment	86
H. Trial	86
IV. Post-Trial and Appeals	87
<b>CHAPTER 5</b>	
<b>Initiating Litigation</b>	<b>89</b>
<hr/>	
I. Parties	89
A. Proper Plaintiffs	89
II. Proper Defendants	90
III. Venue and Jurisdiction	91
A. Subject-Matter Jurisdiction	91
B. Personal Jurisdiction	94
C. Venue	95
IV. Infringement	97
A. 35 U.S.C. § 271(e)	98
B. Differences from Ordinary Patent Infringement	99
V. Juries and the Hatch-Waxman Act	103
A. No Right to a Jury for Section 271(e)(2) Claims	103
B. No Right to a Jury for Counterclaims to Section 271(e)(2) Claims	103
<b>CHAPTER 6</b>	
<b>Responding to the Complaint</b>	<b>105</b>
<hr/>	
I. Introduction to Responses in the Hatch-Waxman Litigation Context	105
II. Pre-Answer Motions	105
A. Motions to Dismiss	105
B. Motion for Sanctions Under Fed. R. Civ. P. 11	126
III. The Answer	127
A. Defenses	127
B. Additional Counterclaims	136
IV. Nonlitigation Alternatives	138
<b>CHAPTER 7</b>	
<b>Discovery</b>	<b>141</b>
<hr/>	
I. Introduction	141
II. Discovery Planning and Conduct of Discovery	142
A. The Issue of “Control” over Discoverable Information	142
B. Discovery and the Thirty-Month Stay	143
C. Discovery from the Patentee’s Perspective	144
D. Discovery from the ANDA Filer’s Perspective	145

III. Electronic Discovery in ANDA Cases	146
IV. ANDA Litigation Discovery Issues	147
A. FDA Filings of the Patentee and Generic Company	147
V. Research and Development Documents	148
VI. Patent Applications	148
VII. Marketing Information	149
VIII. Paragraph IV Certification Letters	149
IX. Attorney-Client and Work-Product Issues	150
X. Prior Litigation Materials	151
XI. Documents Relevant to Validity	151
XII. Settlement Agreements	152
XIII. Extension of the Thirty-Month Stay	152
<b>CHAPTER 8</b>	
<b>Experts</b>	<b>155</b>
<hr/>	
I. Introduction	155
A. Selection of Experts in ANDA Cases	156
B. Timing	157
II. Expert Involvement During Pre-Trial Proceedings	158
A. Expert Involvement in Directing Discovery	158
B. The Expert Report—Legal and Factual Framework	158
C. Expert Testing or Analysis	168
D. Discovery of the Expert’s Documents and Things	170
E. The Expert Deposition	171
F. Trial Preparation of the Expert	172
III. Expert Involvement in Trial	172
A. Qualifications of the Expert	173
B. Expert Use of Demonstratives	176
C. Sources and Evidence on Which the Expert May Rely	178
<b>CHAPTER 9</b>	
<b>Claim Construction</b>	<b>181</b>
<hr/>	
I. General Aspects of Claim Construction	181
A. Claim Construction Principles	182
B. Claim Construction Procedure and Timing Issues	189
II. Claim Construction Specific to ANDA Cases	193
A. Strategic Considerations	193
B. Sources of Evidence	194
C. Claim Construction Issues and Examples	195

III. The Claim Construction Hearing	202
A. Preparing to Argue the Merits	202
B. The Technology Tutorial	203
C. The Claim Construction Presentation and Demonstratives	203
IV. Appealing and Revisiting Claim Construction	203

## CHAPTER 10

### Summary Judgment 205

I. The Ideal Adjudication for a Hatch-Waxman Case	206
A. Objectives of the Hatch-Waxman Act	
Include Early Resolution of Patent Issues	206
B. A Summary Judgment Motion Can Expedite the Adjudication of a Hatch-Waxman Case	208
C. The Judge as Fact-Finder in a Nonjury Case Has More Flexibility in Resolving the Ultimate Dispute	210
D. Uncertainty of the Final Approved ANDA Product Is a Factor in Seeking Summary Judgment for Noninfringement	212
II. Fed. R. Civ. P. 56 and General Legal Principles Relating to Summary Judgment	212
A. A Brief History of Fed. R. Civ. P. 56 and the 1986 Trilogy of Summary Judgment Cases	212
B. Principles of Fed. R. Civ. P. 56, Including the 2010 Amendments	214
III. Factors and Strategies to Consider in Filing a Summary Judgment Motion in a Hatch-Waxman Case	220
A. Timing as a Strategy	220
B. Summary Judgment as a Means for Obtaining an Adversary's Positions	222
C. The Interplay of a Summary Judgment Motion and Patent Claim Construction Proceedings	222
D. A Summary Judgment Motion Can Encourage Settlement Discussions	223
IV. The Summary Judgment Motion Seeking Adjudication of the Infringement Issue	225
A. General Legal Principles Applicable to Deciding Patent Infringement on Summary Judgment	225
B. Summary Judgment for Noninfringement Is Frequently Sought by ANDA Applicants	227
C. The Status of the ANDA Product Is an Important Factor in Determining Infringement on Summary Judgment	229

D. Issues of Fact Frequently Raised by Patentees to Defeat Summary Judgment of Noninfringement	235
V. Motions for Summary Judgment on Patent Validity Issues	235
VI. Motions for Summary Judgment Relating to Patent Enforceability	238
VII. Reconsideration or Appeal of a Summary Judgment Decision	239

**CHAPTER 11****Remedies****241**

I. Introduction	241
II. Section 271(e)(4)(A)—FDA Preclusion Orders	242
A. ANDA Approval Date	242
B. Approved and Unapproved ANDAs	243
C. Post-Patent Expiration Remedy	245
III. Section 271(e)(4)(B)—Injunctions	245
A. Temporary Injunctive Relief	246
B. Permanent Injunctive Relief	263
C. Equitable Defenses	266
D. Scope and Parties Bound	266
E. Enforcing the Injunction Order	268
IV. Section 271(e)(4)(C)—Money Damages	271
A. Monetary Damages Are Unavailable in Most ANDA Cases	271
B. Willfulness	274
C. Exceptional Case	275
D. Interest	276

**CHAPTER 12****Settlement****277**

I. Introduction	277
II. Frequency of Settlement	277
III. Types of Settlement Agreements	278
A. Compensation to Generics	278
B. Authorized Generics	282
C. Licenses to Products and Technologies Outside the Scope of the Litigation	283
D. Co-Promotion and Profit-Sharing	284
E. Joint Venture Agreements	284
IV. Checklist: Considerations and Items to Include in a Settlement Agreement	285
A. Common Interest/Joint Defense Agreements	285
B. Avoiding Antitrust Violations	285

C. No Challenge Provisions	286
D. Releases for Past and Future Infringement	287
E. Most Favored Nation Clauses	287
F. Ability to Transfer ANDA	288
G. Attorney's Fees	288
H. Stockpiling of Generic Drugs	288
V. Disclosure of Settlement Agreements	289
A. Types of Agreements That Must Be Filed	289
B. Filing Requirements	289
C. Enforcement Procedures	290

## **CHAPTER 13**

### **Antitrust**

**293**

I. Overview of Antitrust Issues	293
II. Legal Theories in ANDA Antitrust Cases	294
A. Monopolization (Sherman Act Section 2) Offenses	294
B. Restraints of Trade (Sherman Act Section 1) Offenses	302
C. State Law Claims	303
III. Federal Trade Commission Cases	304
A. Overview of an FTC Investigation	304
B. Federal Trade Commission and Concurrent Private Cases	306
IV. Private Cases	318
V. Remedies	324
A. Money Damages for Antitrust Violation	324
B. Attorneys' Fees Awarded to Generic for Exceptional Case	325
C. Injunctive Relief	326

## **CHAPTER 14**

### **Pretrial Preparation**

**329**

I. Trial Plan and Themes	329
A. Narrowing the Issues	329
B. Burdens of Proof	330
C. Refining Case Themes	334
D. Planning the Trial Presentation	335
II. Selection and Preparation of Witnesses	336
A. Fact Witnesses	336
B. Expert Witnesses	337
III. Exhibits and Demonstratives	337
IV. Trial Consultants and Mock Trials	338
V. Notice Pursuant to 35 U.S.C. § 282	339

VI.	Pretrial Orders and Statements	340
	A. Pretrial Orders	340
	B. Proposed Findings of Fact	342
	C. Local Rules	342
VII.	<i>Daubert</i> Motions	342
VIII.	Motions <i>in Limine</i>	346
	A. Deciding Which Motions to File	346
	B. Motions Common to ANDA Cases	346
IX.	Pre-trial Conferences	348
	A. Scheduling	348
	B. Trial Conduct	348
	C. Order of Proofs and Bifurcation	349
X.	Logistical Preparations	349
	A. For the Courtroom	349
	B. For the Trial Team	350
<b>CHAPTER 15</b>		
	<b>Trial</b>	<b>351</b>
<hr/>		
I.	Introduction	351
II.	The Trial Plan	352
	A. Attitude and Approach	352
	B. Know Your Judge	354
	C. Know Your Pretrial Order	356
	D. Multi-District Litigation and Multi-Defendant Cases	357
	E. Conduct at Trial	358
	F. Courtroom Layout and Technology	359
III.	Opening Statement	360
	A. Introduction	360
	B. Refining the Issues for Trial and the Theme of Your Case	361
	C. Content of Statement	362
IV.	Order of Presentation	363
	A. Case-in-Chief—Stage One	363
	B. Order of Proof Where There Is a Stipulation of Infringement	365
	C. Answering Case and Case-in-Chief—Stage Two	365
	D. Subsequent Stages	365
	E. Timed Trials and Managing the Trial Clock	365
V.	Witnesses	366
	A. Introduction	366
	B. Selection of Trial Fact Witnesses	366
	C. Selection of Trial Expert Witnesses	372
	D. Preparation of Witnesses for Testimony at Trial	375

VI. Examination of Witnesses	381
A. Direct Examination	381
B. Cross-Examination	386
C. Redirect Examination	390
D. Recross-Examination	391
VII. Documentary and Physical Evidence	392
A. Introduction	392
B. Direct Evidence	394
C. Demonstrative Evidence	397
VIII. Closing Argument	400
A. Introduction	400
B. Themes Proven	400
C. Promises Fulfilled	402
<b>CHAPTER 16</b>	
<b>Post-Trial</b>	<b>407</b>
<hr/>	
I. Post-Trial Considerations	407
II. Bench Rulings after the Close of Evidence	407
III. Post-Trial Briefing and Proposed Findings of Fact and Conclusions of Law	409
IV. Motions for a Preliminary Injunction if No Decision Issues Before the Expiration of the Automatic Stay	410
V. Other Post-Trial Applications	412
A. Stay Pending Appeal by Brand	412
B. Permanent Injunction	413
C. Supplementing the Record	414
VI. Procedural Alternatives Before Appeal	415
<b>CHAPTER 17</b>	
<b>Appeals to the Court of Appeals for the Federal Circuit</b>	<b>417</b>
<hr/>	
I. Scope of Review	418
II. Mechanics	420
III. Preparing the Shell	429
A. Introduction	429
B. Jurisdictional Statement	430
C. Statement of the Issues	430
D. Statement of the Case	430
E. Statement of Facts	431
F. Summary of the Argument	432
G. Argument	432
IV. Answering Brief	433
V. Oral Argument	433

## CHAPTER 18 Pharmaceutical Regulation and Litigation in Foreign Countries 437

I. Australia	437
A. The Statutory and Regulatory Scheme	437
B. Notice and Pre-Filing Requirements	442
C. The Litigation Process	444
D. Remedies	446
E. Strategic Recommendations	448
F. Other Issues to Consider	451
II. Brazil	453
A. The Statutory and Regulatory Scheme	453
B. Notice and Pre-Filing Requirements	455
C. The Litigation Process	460
D. Other Issues to Consider	463
III. Canada	465
A. The Statutory and Regulatory Scheme	465
B. The Marketing Approval Process for Drugs	466
C. The Submission and Review Process	467
D. Changes to New Drugs Once Approved	468
E. Biologics, Radiopharmaceuticals, and Genetic Therapies: Key Differences in the Approval Process	469
F. Patented Medicines (Notice of Compliance) Regulations	470
G. Remedies, Damages, and Costs	472
H. Strategic Recommendations	473
I. Other Issues to Consider	473
IV. European Union and United Kingdom	475
A. The Statutory and Regulatory Scheme	475
B. Outline of the EU Regulatory Legal Framework	481
C. Procedures for the Grant of a Marketing Authorization	484
D. Requirements for a Full Application for MA and the Right to Regulatory Data Protection	486
E. Requirements for Abridged Applications for a MA	490
F. Other Legal Bases for an Application for MA	493
G. The Regulatory Regime Relating to Orphan Medicinal Products	494
H. Strategies and Hurdles in the Enforcement of IP Regulatory Rights	497
I. The Interface Between Regulatory IP Rights and Patent Protection	508
J. Conclusion	513
V. Japan	513
A. The Statutory and Regulatory Scheme	513

Appendix Table 1	516
B. The Duration of a Patent Right and Extension System	520
C. Measures That Can Be Taken by a Generic Manufacturer Toward the Patent of Its Corresponding Brand-Name Drug	524
D. The Litigation Process	527
E. Remedies	529
F. Summary and Strategic Recommendation	530
Appendix Table 2	532
Table Notes	534

## **CHAPTER 19**

### **Managing an ANDA Litigation**

535

I. Introduction	535
II. Initial Considerations	536
A. Active Client Communications	536
B. Assembling a Litigation Team	537
C. Experts and Consultants	538
D. Budget	539
III. Management of an ANDA Litigation	541
A. Logistics	541
B. Discovery	542
C. Narrowing the Issues for Trial	547
D. Trial Organization	548
IV. Conclusion	549

## **APPENDICES**

551

Appendix 1	551
Appendix 2	557
Appendix 3	561
Appendix 4	575
Appendix 5	581
Appendix 6	583
Appendix 7	585
Appendix 8	595
Appendix 9	601
Appendix 10	609
Appendix 11	611
Appendix 12	613
Appendix 13	617
Appendix 14	625
Appendix 15	629

Appendix 16	631
Appendix 17	633
Appendix 18	635
Appendix 19	637
Appendix 20	639
Appendix 21	661
Appendix 22	677
Appendix 23	679
Appendix 24	681
Appendix 25	683
Appendix 26	717
Appendix 27	729
Appendix 28	731
Appendix 29	733
Appendix 30	735
Appendix 31	737
Appendix 32	747
Appendix 33	749
Appendix 34	751
Appendix 35	753
Appendix 36	755
Appendix 37	757
Appendix 38	759
Appendix 39	761
Appendix 40	763
Appendix 41	765
<b>INDEX</b>	<b>767</b>

---

<http://www.pbookshop.com>